Search Within

Gynecologic Medicine Service

Formats
  1. Journal Article (1104)
  2. Meeting Abstract (902)
  3. Review (55)
  4. Book Section (46)
  5. Editorial (36)
  6. Guidelines (22)
  7. Correspondence (9)
  8. Miscellaneous (3)
  9. Research Letter (2)
  10. Book Whole (1)
Groups
  1. Solid Tumor Oncology Division (2180)
  2. Department of Medicine (2174)
  3. Gynecology Disease Management Team (1877)
  4. GDMT, Medicine (1859)
  5. Surgery (603)
  6. GDMT, Surgery (479)

More Groups

People
  1. Carol Aghajanian (615)
  2. Nadeem Abu-Rustum (292)
  3. Martee Hensley (290)
  4. Roisin O'Cearbhaill (273)
  5. Vicky Makker (269)
  6. Paul Sabbatini (262)

More People

Years
  1. 2025 (75)
  2. 2024 (167)
  3. 2023 (171)
  4. 2022 (209)
  5. 2021 (163)
  6. 2020 (203)

More Years

Publications
  1. Journal of Clinical Oncology (458)
  2. Gynecologic Oncology (420)
  3. International Journal of Gynecological Cancer (161)
  4. Annals of Oncology (117)
  5. Clinical Cancer Research (71)
  6. Cancer Research (55)

More Publications

Publishers
  1. American Society of Clinical Oncology (498)
  2. Elsevier B.V. (446)
  3. Lippincott Williams & Wilkins (188)
  4. American Association for Cancer Research (173)
  5. Oxford University Press (144)
  6. Elsevier Inc. (128)

More Publishers

Results (2180)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Progression-free and overall survival in newly-diagnosed homologous recombination DNA-repair deficient ovarian cancer without a BRCA mutation
    Meeting Abstract

    Graves, S.; Sullivan, M.; Adkoli, A.; Zhou, Q.; Chi, D.; Ellenson, L.; O'Cearbhaill, R.; Weigelt, B.; Grisham, R.
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Avutometinib plus defactinib in recurrent low-grade serous ovarian cancer: A subgroup analysis of ENGOT-OV60/GOG-3052/ RAMP 201 Part A
    Meeting Abstract

    Banerjee, S.; Van Nieuwenhuysen, E.; Santin, A.; Ring, K.; Colombo, N.; Thaker, P.; Prendergast, E.; Clamp, A.; Ray-Coquard, I.; Chon, H. S.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Clinical activity of tazemetostat, an EZH2 inhibitor, among patients with advanced endometrioid endometrial cancer and ovarian clear cell carcinoma with and without ARID1A mutations (NRG-GY014)
    Meeting Abstract

    Schram, A.; Eskander, R.; Sill, M.; Hagemann, A.; Waggoner, S.; Press, J.; Ghamande, S.; Zivanovic, O.; Bottsford-Miller, J.; Aghajanian, C.
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Overall survival and progression-free survival by PD-L1 status among endometrial cancer patients treated with pembrolizumab plus carboplatin/paclitaxel as compared to carboplatin/paclitaxel plus placebo in the NRG GY018 trial
    Meeting Abstract

    Eskander, R.; Sill, M.; Beffa, L.; Moore, R.; Hope, J.; Musa, F.; Mannel, R.; Shahin, M.; Cantuaria, G.; Girda, E.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy and safety of trastuzumab deruxtecan among patients with HER2-expressing solid tumors: Biomarker and subgroup analyses from the cervical, endometrial, and ovarian cancer cohorts of the DESTINY-PanTumor02 study
    Meeting Abstract

    Makker, V.; Oaknin, A.; Manso, L.; González-Martín, A.; Lugowska, I.; Meric-Bernstam, F.; Lorusso, D.; Banerjee, S.; Liao, J.; Siena, S.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy and safety of alpelisib plus olaparib versus chemotherapy among patients with platinum-resistant or refractory high-grade serous ovarian cancer without BRCA mutation: Primary analysis of the EPIK-O trial
    Meeting Abstract

    Konstantinopoulos, P.; Kim, J. W.; Freyer, G.; Lee, J. Y.; Gaba, L.; Grisham, R.; Colombo, N.; Wu, X.; Sehouli, J.; Cruz, F.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Individualised schedule optimisation improves rates and severity of anaemia in patients (pts) treated with lunresertib (lunre), a PKMYT1 inhibitor, and camonsertib (cam), an ATR inhibitor, in the phase I MYTHIC study (NCT0485565)
    Meeting Abstract

    Højgaard, M.; Yap, T. A.; Lee, E. K.; Weiss, M. C.; Lheureux, S.; Simpkins, F.; LoRusso, P.; Carneiro, B. A.; Moy, R. H.; Aguado-Fraile, E.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Tumor-agnostic efficacy and safety of lirafugratinib, a highly selective FGFR2 inhibitor, in patients (pts) with advanced solid tumors with FGFR2 fusions or rearrangements (f/r): The ReFocus study
    Meeting Abstract

    Hollebecque, A.; Dotan, E.; Liao, C. Y. A.; Roda, D.; Fontana, E.; Babiker, H.; Kim, R. D.; Oh, D. Y.; Ghiringhelli, F.; Moreno, I.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • First clinical results from a phase 1 trial of PRT3789, a first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4
    Meeting Abstract

    Yap, T. A.; Dowlati, A.; Dagogo-Jack, I.; Vibert, J.; Spira, A. I.; Moreno Garcia, V.; Punekar, S. R.; Calvo, E.; Sonpavde, G. P.; Awad, M.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Longer-term safety and efficacy of selinexor maintenance therapy for patients with TP53wt advanced or recurrent endometrial cancer: Follow-up subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study
    Meeting Abstract

    Haluska, P.; Pérez-Fidalgo, J. A.; Vergote, I.; Hamilton, E.; de Giorgi, U.; Van Gorp, T.; Lübbe, K.; Zikan, M.; Helpman, L.; Miller, D. S.; more...
    Asia-Pacific Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save